Literature DB >> 25962712

Contemporary Trends of Optimal Evidence-Based Medical Therapy at Discharge for Patients Surviving Acute Myocardial Infarction From the Korea Acute Myocardial Infarction Registry.

Jang Hoon Lee1, Myung Hwan Bae1, Dong Heon Yang1, Hun Sik Park1, Yongkeun Cho1, Myung Ho Jeong2, Young Jo Kim3, Kee-Sik Kim4, Seung Ho Hur5, In Whan Seong6, Myeong Chan Cho7, Chong Jin Kim8, Shung Chull Chae1.   

Abstract

BACKGROUND: Temporal trends of evidence-based optimal medical therapy (OMT) at discharge after acute myocardial infarction (AMI) have not been investigated in recent years. HYPOTHESIS: OMT should have been increased in AMI and gap between guidelines and practices in its use should have been narrowed.
METHODS: We examined discharge medications of 17,578 post-MI patients who had no documented contraindications to antiplatelet agents, β-blockers, angiotensin-converting enzyme inhibitors, or statins across a 6-year period (divided into subperiods of November 2005 to December 2006 [period 1], 2007 [period 2], 2008 [period 3], 2009 [period 4], 2010 [period 5], and January to June 2011 [period 6]) in the Korean AMI Registry. OMT was defined as use of all 4 indicated medications.
RESULTS: Marked increases in OMT (48.6% to 63.2%) were seen irrespective of age and sex, mainly attributed to marked increases in the use of β-blockers (70.3% to 83.7%) and statins (76.9% to 82.6%) from period 1 to period 6. The gap in use of OMT between men and women narrowed over time between the first and second 3 periods, but not between the young and the elderly. Advanced age (odds ratio [OR]: 0.88, P = 0.04) was independently associated with underuse of OMT. Adjusted ORs for OMT from period 1 to period 6 were as follows: 1, 1.14 (P = 0.024), 1.21 (P = 0.001), 1.40 (P < 0.001), 1.47 (P < 0.001), and 1.69 (P < 0.001), respectively.
CONCLUSIONS: Despite gradual increase in OMT over time, the gap between guidelines and practices in use of OMT continues to exist.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25962712      PMCID: PMC6711002          DOI: 10.1002/clc.22396

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  3 in total

1.  Prescription Rates for Antiplatelet Therapy (APT) in Coronary Artery Disease (CAD) - What Benchmark are We Aiming at in Continuing Medical Education (CME)?

Authors:  Bernd Hagen; Reinhard Griebenow
Journal:  J Eur CME       Date:  2020-10-23

2.  We can do much better than what we did.

Authors:  Sang-Hak Lee
Journal:  Korean J Intern Med       Date:  2020-04-29       Impact factor: 2.884

3.  Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases.

Authors:  Su-Yeon Choi; Bo Ram Yang; Hyun-Jae Kang; Kyong Soo Park; Hyo-Soo Kim
Journal:  Korean J Intern Med       Date:  2019-11-25       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.